EL7.AI
StocksMedium•16 November 2026•
4 min read

Unicycive Posts $0.25 Per-Share Loss in Third Quarter, Reports $59 Million in Liquidity

Key Facts

1The loss was $0.25 per share in the third quarter of 2026, $0.10 below analysts’ expectations.
2Cash and marketable securities totaled about $59 million on September 30, 2026.
3Net loss widened to $7.0 million from $6.0 million a year earlier.
4The company is targeting March 25, 2027, for the FDA’s decision on OLC.

Unicycive Therapeutics reported a net loss of $7.0 million, or $0.25 per share, in the third quarter on November 16, 2026, and said cash and marketable securities totaled about $59 million at the end of September. The per-share loss was $0.10 below analysts’ expectations, according to the headline of a report published by Seeking Alpha. But the improvement against expectations did not prevent the net loss from widening year over year, as the company posted $6.0 million in the same quarter of 2025. The company attributed the widening mainly to higher commercial launch preparation expenses. Investors are focused on the U.S. Food and Drug Administration’s review of the OLC drug application, with a regulatory decision targeted for March 25, 2027.

Net loss attributable to common shareholders was $7.0 million in the third quarter of 2026, compared with $6.0 million a year earlier, according to the company’s announcement. By contrast, loss per share narrowed to $0.25 from $0.33 in the comparable period. StockTitan data showed a net loss of $6.997 million, versus $6.011 million in the third quarter of 2025. Research and development expenses fell to $2.246 million during the quarter. General and administrative expenses rose to $6.595 million, and the company said higher commercial launch preparation costs were the primary factor behind the wider net loss.

The fair value of cash and cash equivalents and investments in marketable securities was $58.972 million on September 30, 2026, according to the company’s quarterly form filed with the U.S. Securities and Exchange Commission. The company described the total as about $59 million and said its expected funding would extend beyond 2027, including the costs of a potential OLC launch. The balance gives the company funding to continue launch preparations while the FDA reviews the application. In its announcement, the company said its focus was to continue preparations alongside the regulatory review. A potential launch remains contingent on approval, and the company has not announced that the drug has received it.

The OLC application received a complete response letter from the FDA in June 2026, and the company said the letter addressed deficiencies previously identified at the product’s original manufacturing supplier. It added that the letter raised no concerns about clinical efficacy or safety data and did not request additional data from the company. The resubmission subsequently included chemistry, manufacturing and controls data from a new supplier, according to the announcement that the resubmission was accepted. The new supplier’s facility was last inspected by the FDA in March 2024 and received a “no action indicated” classification. These details provide background on the ongoing review, while the final decision rests with the regulator.

The company set March 25, 2027, as its target date for a regulatory decision under the Prescription Drug User Fee Act, and Chief Executive Shalabh Gupta said work on launch preparations would continue alongside the FDA review. The company also plans to bring on commercial leaders during the first quarter of 2027. If OLC is approved, it expects to hire a sales team focused on prescribing physicians. On treatment funding, the company said the Centers for Medicare & Medicaid Services established a permanent add-on of $12.85 per treatment session to the base payment rate, effective January 1, 2027. The change is intended to fund phosphate binders within the dialysis bundle after separate transitional payments for the current binders end.

In premarket trading ahead of the earnings announcement, UNCY shares closed at $3.55 on November 13, 2026, according to EL7 data. That price is the close of a session before the announcement published on November 16. The data available here did not include a closing price for the announcement date, so $3.55 remains a reference for the November 13 session only. The stock’s performance comes as the company continues to post quarterly losses and the next stage of its commercial plan depends on the review of the OLC application. The target regulatory date is March 25, 2027.

Open on chart